Targeted drug conjugates are reshaping cancer therapy, and trastuzumab emtansine (T-DM1, Kadcyla) stands at the forefront by combining antibody specificity with cytotoxic potency.This market analysis delves into growing demand, regulatory shifts, emerging indications, and competitive dynamics in the trastuzumab emtansine landscape. Introduction Trastuzumab emtansine is an antibody-drug...